Sodium-Glucose Transporter 2 Inhibitors (SGLT2-inhibitors), originally developed for type 2 diabetes mellitus (T2DM), are now pivotal in managing heart failure across the entire spectrum of ejection fraction and chronic kidney disease (CKD).1, 4 With prescriptions doubling in the US from roughly 7 to 14 million between 2015 and 20205 and approximately 1.7 million people being eligible for SGLT2-inhibitors in the UK,6 their use is surging. The gene discussed is SLC5A2; the disease is heart failure.